AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04502264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand of Hope
Description: A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
Study NCT04502264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: A safe agent representing the gold standard treatment for focal spasticity.
Study NCT04502264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A injection
Description: A safe agent representing the gold standard treatment for focal spasticity.
Study NCT02202213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02202213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Study NCT00918320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide/Hycamtin (Topotecan)
Description: Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes
Study NCT04018820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
Study NCT00003675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: 1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
Study NCT01346787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
Description: Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
Study NCT02849483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
Study NCT02849483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
Study NCT04015284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block + Posterior Cord Block
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
Study NCT03314402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Dihydrochloride Monohydrate
Description: Active Substance
Study NCT04618640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV combination vaccine
Description: Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
Study NCT04015284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Brachial Plexus Block
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
Study NCT03965884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: Physical therapy and rehabilitation
Study NCT03811925 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty and drug coated balloon of the superficial femoral artery (SFA)
Description: In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
Study NCT03314402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT04880525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
Study NCT02707874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI 0.2% ropivacaine
Description: Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
Study NCT02707874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIB 0.2% ropivacaine
Description: Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
Study NCT03811925 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty and stenting of the superficial femoral artery (SFA)
Description: In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
Study NCT00052091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
Study NCT00052091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Supportive Therapy
Description: A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
Study NCT02455661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Band (TM)
Study NCT02455661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioSeal
Study NCT02455661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StarClose
Study NCT01380535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP Methoxsalen
Description: Methoxsalen delivered by ECP
Study NCT01380535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Study NCT01380535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Study NCT02013206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Erlotinib tablets taken orally once daily in the morning.
Study NCT00572585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study NCT00572585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04140851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber intervention
Description: Dietary intervention
Study NCT04140851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal diet
Description: Normal diet
Study NCT04744142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone supplementation
Description: Subjects receive either placebo or ketone ester supplementation
Study NCT04744142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Description: Subjects receive either normal or increased protein intake
Study NCT01531439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Naloxone infusion 0.5 mcg/kg/hr
Study NCT01531439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone infusion 2.5 mcg/kg/hr
Study NCT02583958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 3103166
Description: URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
Study NCT02583958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Extra
Description: Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
Study NCT03196219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: C16G2
Study NCT03196219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Varnish Placebo
Study NCT01901198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
Description: Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
Study NCT01901198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon 180 mcg single dose S.C.
Description: Pegasys 180 mcg S.C. single dose on Day 0
Study NCT04614753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dealcoholized Muscadine Wine
Description: 300 ml of Dealcoholized Muscadine Wine
Study NCT01059799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study NCT04614753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Beverage
Description: 300ml of Sugar Water and Acid Content
Study NCT01059799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study NCT01447095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin 1 ng/kg/min
Description: Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
Study NCT01447095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin 2 ng/kg/min
Description: Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
Study NCT01447095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous i.v. infusion with placebo day 5-10 after SAH
Study NCT00821977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT00821977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04128267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPC-1000
Description: Delivers pressure to thumbnail for five seconds at a time
Study NCT04128267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Scan of brain using Magnetic resonance imaging
Study NCT04128267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Administration of questionnaires via computer
Study NCT02726646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
Study NCT02726646 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical debridement
Description: Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
Study NCT02726646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Description: Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
Study NCT02726646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The application of 1 mg of microspheres placebo
Study NCT03954756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and PD1
Description: 1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Study NCT00750204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APRV
Description: APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV.
Study NCT00750204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional MV
Description: Low tidal-volume mechanical ventilation
Study NCT02519192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.Ulta™ Negative Pressure Wound Therapy System
Description: VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
Study NCT02519192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vac sponge irrigations
Description: VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
Study NCT02519192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ostomy bag
Description: Non Vac Arm will receive ostomy bag applications.
Study NCT02519192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wet to dry dressings
Description: Non Vac arm will receive wet to dry dressing changes.
Study NCT04672928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80mg/m\^2,iv,Q4W
Study NCT04672928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 300mg,iv,Q4W
Study NCT00647790 — intervention group
Intervention type: PROCEDURE
Intervention: PET scan with injection of 5-8 mCi of 18FES
Description: Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
Study NCT03590379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 DPI
Description: BDP/FF/GB DPI
Study NCT03590379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF5993 pMDI
Description: BDP/FF/GB pMDI
Study NCT03590379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 pMDI
Description: BDP/FF pMDI
Study NCT03590379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DPI
Description: CHF 5993 DPI matched placebo
Study NCT03590379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pMDI
Description: CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
Study NCT00378196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg/0.05 ml dose
Study NCT00378196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg/0.05 ml dose
Study NCT00924456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: a natural effortless mental technique
Study NCT00924456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Transcendental Meditation program
Description: a natural effortless mental technique
Study NCT01554384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Description: Automated nucleic-acid amplification test (fully integrated) test for TB
Study NCT01554384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Study NCT02625259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 capsules
Study NCT02625259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT02625259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets
Study NCT01075945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin- piperaquine
Description: three tablets per day
Study NCT01075945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether- lumefantrine
Description: twenty tablet in eight doses
Study NCT01075945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether- lumefantrine
Description: twenty tablet in eight doses
Study NCT01905657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01905657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT02955485 — intervention group
Intervention type: OTHER
Intervention: Patients do not undergo any type of interventions, but standard care if offered and accepted.
Study NCT01010516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose rosuvastatin
Description: 40 of rosuvastatin daily
Study NCT01010516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin plus fenofibrate
Description: Existing statin plus micronised fenofibrate 200 mg daily
Study NCT01010516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin plus niacin ER/laropiprant
Description: Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
Study NCT01737151 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01737151 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: four fraction split-course SBRT
Description: four fraction split-course SBRT
Study NCT01409655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Description: . Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
Study NCT02538250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricomp Drink Plus
Description: Oral nutritional supplementation
Study NCT01896440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)